What's Happening?
Guardant Health and Quest Diagnostics have announced a strategic collaboration to broaden access to Guardant's Shield blood-based colorectal cancer screening test in the United States. Shield is the first blood test to receive full FDA approval for colorectal cancer screening in average-risk adults aged 45 and older. The collaboration will enable Quest's provider clients to order Shield through their existing accounts, facilitating access to the test across Quest's extensive network.
Why It's Important?
Colorectal cancer is a leading cause of cancer-related deaths in the U.S., with early detection significantly improving survival rates. The Shield test offers a non-invasive, convenient alternative to traditional screening methods, potentially increasing screening rates among eligible adults. By leveraging Quest's vast network, the collaboration aims to enhance early detection and improve patient outcomes. This partnership underscores the importance of innovative diagnostic solutions in cancer prevention and management.
What's Next?
Shield is expected to be available for physician order through Quest in the first quarter of 2026. Quest's national sales team will educate healthcare providers about the test, aiming to accelerate its adoption. The collaboration could set a precedent for similar partnerships in the diagnostic industry, highlighting the role of strategic alliances in expanding access to cutting-edge healthcare technologies.
